Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy By Ogkologos - March 9, 2026 92 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from multiomic profiling in the CITN-12 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Adopts a Positive Opinion for a New Route of Administration Together with a New Pharmaceutical Form and a New Strength for Isatuximab National Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC MOST POPULAR Get the Most out of Seasonal Fruits! December 28, 2020 Biosimilars for Cancer Emerge as Patents on Widely Used Biological Drugs... June 18, 2018 Opinion: “There’s cause for optimism in 2021 and beyond” December 30, 2020 The IGCCCG Update Model Allows Improved and More Granular Individual Prognostic... April 16, 2021 Load more HOT NEWS Veteran Dresses As Captain America & Brings Joy To Children In... Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells FDA Approves Niraparib and Abiraterone Acetate Plus Prednisone for BRCA2-mutated Metastatic Castration-Sensitive Prostate Cancer New Measures to Avoid Handling Errors with Leuprorelin Depot Medicines
